Guest guest Posted December 22, 2010 Report Posted December 22, 2010 Dear Parents of Autism and Aspergers Treatment, We are and Neil Shekar, land residents at Winston Churchill High School, and we are interns for the international FEND-Folate Study sponsored by town University Medical Center (IRB # 2009-162) and the Interactive Autism Network (Project # SR0039). "FEND" stands for fetal exposure to neuroactive drugs. Many families who are affected by autism spectrum and other pervasive developmental disorders are not included in medical studies and birth registries that track longer term childhood outcomes of prenatal exposure to neuroactive medications and folate. The FEND Study would like you to be our collaborator and help us disseminate this online risk assessment survey: http://www.surveymonkey.com/s.aspx?sm=qY4du_2bdtYao2HumBxcYjRA_3d_3d . This link takes you to a letter from the principal investigator that explains the impetus and specific aims of this initiative. If you read the letter and choose to participate in the survey, please know that participation is anonymous, encrypted, and takes 5 minutes to complete. Thank you for your cooperation! You are welcome to contact the principal investigator Dr. McVearry if you have any questions (301-651-6662 or fendstudy@...). Thank you for helping us accelerate understanding about prenatal exposure to neuroactive drugs and folate! and Neil Shekar Knowledge Gap: Human Studies of Prenatal Exposure to Neuroactive Medications As a medication class, anticonvulsant drugs ran fifth among the most prescribed drugs in the United States, with over 56 million prescriptions written in 2004 (IMS Health). Additionally, 48 million women of child-bearing age took antiepileptic drugs in survey year 2000, according to the U.S. Census Bureau statistics reported by Epilepsy Society of America. While several human studies explicitly link autism and prenatal exposure to anticonvulsant medications, this literature has three crucial limitations. First, human studies are primarily limited to valproate exposures. Second, human studies are predominantly based on case report and retrospective enrollment methods, not currently available for this medication class, and the population attribute risk (PAR) for autism has not been investigated. The information collected in this survey will enable us to develop a database with improved power for generating hypotheses regarding risks of autism spectrum outcomes from specific neuroactive medications. Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.